Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate...
ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label in metastatic...
Author: Fierce Pharma
Read Original Article